Letter

Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: How strong is the evidence?

BMJ 2005; 331 doi: http://dx.doi.org/10.1136/bmj.331.7530.1474 (Published 15 December 2005) Cite this as: BMJ 2005;331:1474
  1. Bernard G Bannwarth, professor of therapeutics ([email protected])
  1. University Hospital, 33076 Bordeaux, France

    EDITOR—The major conclusion drawn from the nested case-control study by Hippisley-Cox et al was that no consistent evidence was found of enhanced safety against gastrointestinal events with any of the new cyclo-oxygenase-2 (COX-2) inhibitors compared with non-selective non-steroidal anti-inflammatory …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe